DV
Dividend Vision

BDTX — Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc (BDTX)

Total return is -94.9% over the past 6.5 years, 254.8 points behind SPY at 159.9%. Its deepest 1-year drawdown was 66.9%.

Black Diamond Therapeutics Inc is an individual equity stock, not an ETF, and therefore does not have a defined dividend strategy, distribution frequency, or expense ratio typical of ETF products. As a single biotech company stock in the therapeutic development space, it does not generate a consistent yield profile or regular distributions. This holding appeals primarily to growth-oriented investors seeking exposure to early-stage pharmaceutical innovation rather than income-focused investors seeking regular dividend payments.

BDTX key facts

Asset type
Stock
Asset class
Equity
Inception date
01/30/2020
Last close
$2.02
Market cap
$102,570,176
Average volume
330400.0
Beta
3.252
Payout ratio
0.0
Forward P/E
8.3333
EPS
$-0.77